Novo Nordisk's CagriSema Shows Major Weight Loss In Late-Stage Trial
22/6 19:11
(RTTNews) - Novo Nordisk's (NVO) Phase 3 REDEFINE 1 trial found that treatment with CagriSema led to a 22.7% weight loss at 68 weeks among patients who adhered to the treatment, compared to 2.3% in the placebo group. When evaluating all participants, regardless of adherence, the...